Target Name: RBM4
NCBI ID: G5936
Review Report on RBM4 Target / Biomarker Content of Review Report on RBM4 Target / Biomarker
RBM4
Other Name(s): DKFZp547K0918 | Transcriptional coactivator CoAZ | transcriptional coactivator CoAZ | MGC75138 | ZCCHC21 | RNA binding motif protein 4, transcript variant 1 | RNA binding motif protein 4 | RNA-binding protein 4 (isoform 1) | Zinc finger CCHC-type and RNA binding motif 3A | RBM4A | RBM4_HUMAN | OTTHUMP00000219043 | RBM4 variant 1 | OTTHUMP00000235525 | zinc finger CCHC-type and RNA binding motif 3A | OTTHUMP00000205226 | ZCRB3A | OTTHUMP00000235523 | LARK | RNA-binding motif protein 4a | hLark | OTTHUMP00000205224 | OTTHUMP00000205225 | FLJ36727 | Lark homolog | RNA-binding motif protein 4 | lark homolog | RNA-binding protein 4

RBM4: A Potential Drug Target and Biomarker for Diseases

The rapid development of new therapeutic approaches for diseases has led to an increasing interest in the research of potential drug targets and biomarkers. One such target that has garnered significant attention in recent years is RBM4 (DKFZp547K0918), a gene that has been identified as a potential drug target in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

In this article, we will provide an overview of RBM4, its functions, potential drug targets, and its potential as a biomarker.

Functions of RBM4

RBM4 is a gene that encodes a protein known as BM4, a member of the superfamily of RNA-protein dinucleotide binding protein (SNP-BP). BM4 is involved in various cellular processes, including cell adhesion, migration, and invasion. It is also involved in the regulation of cell cycle progression and in the establishment of the microenvironment in the development of cancer.

Potential Drug Targets

RBM4 has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for disease progression. The following are some of the potential drug targets for RBM4:

1.Cancer

RBM4 has been shown to be involved in the regulation of cell cycle progression, which is a critical step in cancer development. It has been shown to play a role in the development of various types of cancer, including breast, ovarian, and prostate cancer.

2. Neurodegenerative Disorders

RBM4 has been shown to be involved in the regulation of the nervous system, which is crucial for the proper functioning of the brain. It has been linked to the development and progression of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

3. Autoimmune Diseases

RBM4 has been shown to be involved in the regulation of immune system function, which is crucial for the immune response against infections and diseases. It has been linked to the development and progression of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

Potential as a Biomarker

RBM4 has also been shown to be potential as a biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The ability to detect and measure the expression of RBM4 has the potential to aid in the development of new diagnostic tests and therapies.

Conclusion

RBM4 is a gene that has been identified as a potential drug target and biomarker for various diseases. Its functions include cell adhesion, migration, and invasion, as well as the regulation of cell cycle progression and the establishment of the microenvironment in cancer development. The potential drug targets for RBM4 include cancer, neurodegenerative disorders, and autoimmune diseases. Furthermore, RBM4 has the potential to act as a biomarker for these diseases, which could aid in the development of new diagnostic tests and therapies.

Targeting RBM4

The development of new therapeutic approaches for diseases depends on the identification of effective drug targets. RBM4 is an attractive target due to its involvement in various cellular processes that are crucial for disease progression. The following are some of the potential strategies for targeting RBM4:

1. small molecule inhibitors:

Small molecules can be developed to inhibit the activity of RBM4, targeting its various functions. For instance, inhibitors can be developed to inhibit the activity of RBM4 in cell adhesion, migration, and invasion.

2. RNA-based therapeutics:

RBM4 can be targeted using RNA-based therapeutics, such as RNA interference (RNAi) and RNA-based inhibitors. These therapeutics can be designed to specifically target RBM4 mRNA levels and prevent its translation into proteins.

3. Monoclonal antibodies:

Monoclonal antibodies can be developed to target RBM4, either by targeting its protein product or by targeting its mRNA. These antibodies can be used for diagnostic or therapeutic purposes, depending on the disease being treated.

Conclusion

RBM4 is a gene that has the potential to revolutionize our understanding of disease and the development of new therapeutic approaches. Its functions include cell adhesion, migration, and invasion, as well as the regulation of cell cycle progression and the establishment of the microenvironment in cancer development. The potential drug targets for RBM4 include cancer, neurodegenerative disorders, and autoimmune diseases. Furthermore, RBM4 has the potential to act as a biomarker for these diseases.

Targeting RBM4

To develop new therapeutic approaches for diseases, the identification of effective drug targets is critical. RBM4 is an attractive target due to its involvement in various cellular processes that are crucial for disease progression. The following are some of the potential strategies for targeting RBM4:

1. small molecule inhibitors:

2. RNA-based therapeutics:

3. Monoclonal antibodies:

Acknowledgments

We would like to thank the funding agencies that have supported our research in this area, as well as the researchers who have contributed to our understanding of RBM4 and its potential as a drug target and biomarker.

Protein Name: RNA Binding Motif Protein 4

Functions: RNA-binding factor involved in multiple aspects of cellular processes like alternative splicing of pre-mRNA and translation regulation. Modulates alternative 5'-splice site and exon selection. Acts as a muscle cell differentiation-promoting factor. Activates exon skipping of the PTB pre-mRNA during muscle cell differentiation. Antagonizes the activity of the splicing factor PTBP1 to modulate muscle cell-specific exon selection of alpha tropomyosin. Binds to intronic pyrimidine-rich sequence of the TPM1 and MAPT pre-mRNAs. Required for the translational activation of PER1 mRNA in response to circadian clock. Binds directly to the 3'-UTR of the PER1 mRNA. Exerts a suppressive activity on Cap-dependent translation via binding to CU-rich responsive elements within the 3'UTR of mRNAs, a process increased under stress conditions or during myocytes differentiation. Recruits EIF4A1 to stimulate IRES-dependent translation initiation in respons to cellular stress. Associates to internal ribosome entry segment (IRES) in target mRNA species under stress conditions. Plays a role for miRNA-guided RNA cleavage and translation suppression by promoting association of AGO2-containing miRNPs with their cognate target mRNAs. Associates with miRNAs during muscle cell differentiation. Binds preferentially to 5'-CGCGCG[GCA]-3' motif in vitro

The "RBM4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBM4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1 | RCHY1 | RCL1 | RCN1 | RCN1P2 | RCN2 | RCN3 | RCOR1 | RCOR2 | RCOR3 | RCSD1 | RCVRN | RD3 | RD3L | RDH10 | RDH11 | RDH12 | RDH13 | RDH14 | RDH16 | RDH5 | RDH8 | RDM1 | RDUR | RDX | RDXP2 | Reactive oxygen species (ROS) | REC114 | REC8 | RECK | RECQL | RECQL4 | RECQL5 | REELD1 | REEP1 | REEP2 | REEP3 | REEP4 | REEP5